Researchers report results of the first-in-human phase 1 clinical trials of a novel immunotherapy approach for solid tumors expressing glypican-3 (GPC3). A team from Baylor College of Medicine and Texas Children’s Cancer Center led the study, which tested chimeric antigen receptor (CAR) T cells enhanced with the protein interleukin-15 (IL-15). The findings are published in Nature.
Medical Xpress – latest medical and health news stories
